C4 Therapeutics (CCCC) Operating Expenses (2019 - 2026)

C4 Therapeutics has reported Operating Expenses for 8 years, with the latest figure at $33.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 6.77% year-over-year to $33.9 million; the trailing twelve-month figure through Mar 2026 stood at $148.7 million (down 4.89% YoY), and the FY2025 full-year result was $151.2 million, down 2.6% from the prior year.
• Operating Expenses for Q1 2026 stood at $33.9 million, down from $34.2 million in the prior quarter.
• The five-year high for Operating Expenses was $45.6 million in Q3 2025, with the low at $33.4 million in Q2 2024.
• Average Operating Expenses over 5 years is $38.9 million, with a median of $39.2 million recorded in 2022.
• Year-over-year, Operating Expenses soared 39.69% in 2022 and retreated 20.34% in 2025.
• Tracing CCCC's Operating Expenses over 5 years: stood at $41.1 million in 2022, then dropped by 1.12% to $40.7 million in 2023, then grew by 5.4% to $42.9 million in 2024, then slipped by 20.34% to $34.2 million in 2025, then slipped by 0.66% to $33.9 million in 2026.
• The last three Operating Expenses figures came in at $33.9 million (Q1 2026), $34.2 million (Q4 2025), and $45.6 million (Q3 2025), per Business Quant data.

Peer Comparison